公开(公告)号：US20170087201A1

公开(公告)日：2017-03-30

申请号：US15359555

申请日：2016-11-22

Applicant: Development Center for Biotechnology

Inventor： Rey Yuh Wu ,  Yu-Yuan Wu ,  Lung-Yu Kuan ,  Klim King

IPC: A61K36/906

CPC classification number: A61K36/906 ,  A61K2236/13 ,  A61K2236/15 ,  A61K2236/17 ,  A61K2236/30 ,  A61K2236/53

Abstract: The present invention is related to the use of an overground part of Hedychium coronarium Koenig in lowering blood glucose, increasing insulin levels and treating and/or preventing diabetes without overly reducing blood glucose in a subject; i.e., not reducing blood glucose in a fasting subject. The present invention also relates to an extract and composition of the overground part of Hedychium coronarium Koenig and its use in lowering blood glucose, increasing insulin levels and treating and/or preventing diabetes.

公开(公告)号：US09428575B2

公开(公告)日：2016-08-30

申请号：US14145583

申请日：2013-12-31

Applicant: Development Center for Biotechnology ,  DCB-USA LLC

Inventor： Jiann-Shiun Lai ,  Hung-Ling Wang ,  Chao-Yang Huang ,  Ying-Yung Lok ,  Yuan-Tsong Chen ,  Woan-Eng Chan ,  Chih-Yung Hu

IPC: C07K16/18

CPC classification number: C07K16/18 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

Abstract: An anti-granulysin antibody, or an scFv or Fab fragment thereof, capable of binding to an epitope region from R64 to R113 of granulysin and capable of neutralizing an activity of granulysin. The antibody may contain a sequence selected from the sequences of SEQ ID NO:82 to SEQ ID NO:195, or the antibody may contain a sequence selected from the sequences of SEQ ID NO:39 to SEQ ID NO:76. The antibody may be a monoclonal antibody. A method for treating or preventing an unwanted immune response disorder includes administering to a subject in need thereof an effective amount of an anti-granulysin antibody capable of neutralizing the activity of granulysin. The unwanted immune response disorder may be SJS, TEN, or GVHD.

Abstract translation: 能够结合到颗粒溶素的R64至R113的表位区并能够中和颗粒溶素活性的抗颗粒溶素抗体或其scFv或Fab片段。 抗体可以含有选自SEQ ID NO：82至SEQ ID NO：195的序列的序列，或者抗体可以含有选自SEQ ID NO：39至SEQ ID NO：76的序列的序列。 抗体可以是单克隆抗体。 用于治疗或预防不需要的免疫应答障碍的方法包括向有需要的受试者施用有效量的能够中和颗粒溶素活性的抗颗粒溶素抗体。 不想要的免疫应答障碍可以是SJS，TEN或GVHD。

公开(公告)号：US20160130336A1

公开(公告)日：2016-05-12

申请号：US14895297

申请日：2014-12-29

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY ,  DCB-USA LLC

Inventor： Jiann-Shiun Lai ,  Yan-Da Lai ,  Yen-Yu Wu ,  Yi-Jiue Tsai ,  Yu-Ying Lin

IPC: C07K16/22

CPC classification number: C07K16/22 ,  A61K2039/505 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

Abstract: An anti-VEGF antibody, or a binding fragment thereof, includes a heavy-chain variable region that comprises: (1) a CDRH1 sequence selected from SEQ ID NO: 17, 20, 23, 26, 29, 32, 35, or 38), (2) a CDRH2 sequence selected from SEQ ID NO:18, 21, 24, 27, 30, 33, 36, or 39, and (3) a CDRH3 sequence selected from SEQ ID NO:19, 22, 25, 28, 31, 34, 37, or 40; and a light-chain variable region that comprises: (1) a CDRL1 sequence selected from SEQ ID NO: 41, 44, 47, 50, 53, 56, 59, or 62, (2) a CDRL2 sequence selected from SEQ ID NO: 42, 45, 48, 51, 54, 57, 60, or 63, and (3) a CDRL3 sequence selected from SEQ ID NO: 43, 46, 49, 52, 55, 58, 61, or 64. A method for treating or preventing a VEGF-related disorder, e.g., diabetic retinopathy, age-related macular degeneration, or cancer, uses the antibodies.

Abstract translation: 抗VEGF抗体或其结合片段包括重链可变区，其包含：（1）选自SEQ ID NO：17,20,23,26,29,32,35或38的CDRH1序列 ），（2）选自SEQ ID NO：18,21,24,27,30,33,36或39的CDRH2序列，和（3）选自SEQ ID NO：19,22,25， 28，31，34，37或40; 和轻链可变区，其包含：（1）选自SEQ ID NO：41,44,47,50,53,56,59或62的CDRL1序列，（2）选自SEQ ID NO： ：42,45,48,51,54,57,60或63，和（3）选自SEQ ID NO：43,46,49,52,55,58,61或64的CDRL3序列。一种方法 用于治疗或预防VEGF相关病症，例如糖尿病性视网膜病变，年龄相关性黄斑变性或癌症，使用抗体。

公开(公告)号：US20150183884A1

公开(公告)日：2015-07-02

申请号：US14142186

申请日：2013-12-27

Applicant: NATIONAL HEALTH RESEARCH INSTITUTES ,  DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： Shih-Chong Tsai ,  Neng-Yao Shih ,  Ta-Tung Yuan ,  Ko-Jiunn Liu ,  Shih-Chi Tseng ,  Chih-Yung Hu ,  Hsin-Yun Wang ,  Li-Tzong Chen

IPC: C07K16/40 ,  G01N33/574

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/57492 ,  G01N2333/988

Abstract: The present invention discloses an anti-human alpha-enolase (ENO1) antibody, which can bind the peptides, comprising amino-acid sequence 296FD Q D D W G A W Q K F TA309 (SEQ ID: #9) and/or 326K R I A K A V N EK S336 (SEQ ID: #10) of human ENO1 protein (GenBank: AAH50642.1), has a favorable binding activity (the binding affinity is around 2.19×10-10 mol/L) and a remarkable capability to inhibit the cell invasion and tumor metastasis of a varied of tumors. The recognized peptides and antibody of the invention are useful for diagnosis, prognosis, and treatment of cancers that have been reported to express cell-surface ENO1 such as including lung, breast, pancreas, liver, colorectal, prostate cancers and solid tumors.

Abstract translation: 本发明公开了可以结合肽的抗人α-烯醇酶（ENO1）抗体，其包含氨基酸序列296FD QDDWGAWQKF TA309（SEQ ID：＃9）和/或326K RIAKAVN EK S336（SEQ ID＃＃10 ）的人类ENO1蛋白（GenBank：AAH50642.1）具有良好的结合活性（结合亲和力约为2.19×10 -10 mol / L），并且具有显着的抑制多种肿瘤细胞侵袭和肿瘤转移的能力 。 公认的本发明的肽和抗体可用于已经报道表达细胞表面ENO1的癌症的诊断，预后和治疗，所述癌症包括肺，乳腺，胰腺，肝脏，结肠直肠癌，前列腺癌和实体瘤。

公开(公告)号：US08961971B2

公开(公告)日：2015-02-24

申请号：US13720573

申请日：2012-12-19

Applicant: Development Center for Biotechnology ,  DCB-USA LLC

Inventor： Yu-Shen Hsu ,  Show-Shan Sheu ,  Ming-I Chang ,  Ming-Chuan Chang ,  Ta-Tung Yuan

IPC: A61K39/00 ,  A61K39/395 ,  A61K38/00 ,  A61K38/04 ,  C07K5/00 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00 ,  C12P21/08 ,  A61K38/10 ,  A61K38/16 ,  A61K38/08 ,  C07K16/46 ,  C07K7/06 ,  C07K7/08 ,  C07K16/28

CPC classification number: C07K16/468 ,  C07K7/06 ,  C07K7/08 ,  C07K16/2809 ,  C07K16/2887 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/94

Abstract: This invention relates to bispecific antibodies having combinations of linker and hinge sequences to create linker-hinge interface domains with biological significance. Such linker-hinge interface domains covalently join two molecules, maintain the biological activities of linked molecules (target binding), stabilize the biological characteristics of new molecule (solubility and 4° C. stability), maintain the chemical, biochemical and physical properties (cytotoxicity) of the linked molecules, and modulate the biological characteristics of the linked molecules (activating T-lymphocytes without significant sign of proliferations). Both linker (GGGGS) and hinge (CPPCP) sequences are required to establish functional linker-hinge interface domains as deletion of any of the component resulted in significant lost of T-lymphocyte mediated activity.

Abstract translation: 本发明涉及具有接头和铰链序列组合的双特异性抗体以产生具有生物学意义的接头 - 铰链界面结构域。 这种接头 - 铰链界面域共价连接两个分子，保持连接分子的生物活性（靶结合），稳定新分子的生物学特性（溶解度和4℃稳定性），保持化学，生化和物理性质（细胞毒性 ），并调节连接分子的生物学特性（活化T淋巴细胞而没有显着增殖迹象）。 需要两种接头（GGGGS）和铰链（CPPCP）序列来建立功能性接头 - 铰链界面区域，因为任何组分的缺失导致T淋巴细胞介导的活性的显着丧失。

公开(公告)号：US20130309337A1

公开(公告)日：2013-11-21

申请号：US13872723

申请日：2013-04-29

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： REY-YUH WU ,  YUH-SHAN CHUNG ,  YU-YUAN WU ,  MA-LI SIU ,  CHIN-WEN HSIAO

IPC: A61K36/53 ,  A61K36/23

CPC classification number: A61K36/53 ,  A61K36/23

Abstract: The present invention provides a process for the preparation of Plectranthus amboinicus extracts using a stirring separation method. The present invention also relates to a pharmaceutical composition comprising the Plectranthus amboinicus crude extract and/or extract for treating skin disorders, including enhancing the healing of wounds, especially in diabetic patients.

公开(公告)号：US20250136709A1

公开(公告)日：2025-05-01

申请号：US18944819

申请日：2024-11-12

Applicant: Development Center for Biotechnology

Inventor： Chun-Chung LEE ,  Yu-Hsun LO ,  Chu-Bin LIAO ,  Chen-Jei HONG ,  Sih-Yu CHEN ,  Yen-Yu WU ,  Szu-Liang LAI ,  Chih-Yung HU ,  Wen-Bin KE ,  Ya-Ting JUAN ,  Kao-Jean HUANG

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00

Abstract: The present invention relates to a novel antibody, an antigen-binding fragment thereof and the uses of the antibody and fragment, wherein the antibody and the fragment comprise specific complementarity-determining regions (CDRs) and/or specifically bind to human CD73 at specific epitopes.

公开(公告)号：US12202899B2

公开(公告)日：2025-01-21

申请号：US17256999

申请日：2019-07-14

Applicant: Development Center for Biotechnology

Inventor： Cheng-Chou Yu ,  Shih-Rang Yang ,  Tsung-Han Hsieh ,  Mei-Chi Chan ,  Shu-Ping Yeh ,  Chuan-Lung Hsu ,  Ling-Yueh Hu ,  Chih-Lun Hsiao

IPC: C07K16/28 ,  A61K47/68

Abstract: An anti-PD-L1 antibody, or an antigen-binding fragment thereof, comprising: a heavy chain variable region comprising the three CDRs with the sequences of SEQ ID NOs: 2-4, 6-8, 10-12, 14-16, or 18-20; and/or a light chain variable region comprising the three CDRs with the sequences of SEQ ID NOs: 22-24, 26-28, 30-32, 34-36, or 38-40, wherein the antibody is a chimeric, humanized, composite, or human antibody.

公开(公告)号：US12043668B2

公开(公告)日：2024-07-23

申请号：US17413496

申请日：2019-12-13

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： Chen-Hsuan Ho ,  Chu-Bin Liao ,  Yu-Kai Chen ,  Chen-Wei Huang ,  Tze-Ping Yang ,  Szu-Liang Lai

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2866 ,  A61P35/00 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: An antibody, or an antigen-binding fragment thereof, that binds specifically to human CSF-1R includes a heavy chain variable domain that contains a HCDR1 region having the sequence of SEQ ID NO: 4, a HCDR2 region having the sequence of SEQ ID NO: 5, and a HCDR3 region having the sequence of SEQ ID NO: 6; and a light chain variable domain that contains a LCDR1 region having the sequence of SEQ ID NO: 7, a LCDR2 region having the sequence of SEQ ID NO: 8, and a LCDR3 region having the sequence of SEQ ID NO: 9. The heavy chain variable domain comprises the sequence of SEQ ID NO: 2, and wherein the light chain variable domain comprises the sequence of SEQ ID NO: 3.

公开(公告)号：US20240197780A1

公开(公告)日：2024-06-20

申请号：US18542884

申请日：2023-12-18

Applicant: Development Center for Biotechnology

Inventor： Li-Shuang AI ,  Yu-Hsun LO ,  Cheng-Chou YU ,  Yi-Jiue TSAI ,  Hsin-Yi TSAI ,  Show-Shan SHEU ,  Yi-Tian HE ,  Pei-Yi TSAI ,  Chia-Tsen LAI

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464411 ,  A61K39/464429 ,  A61P35/00 ,  C07K14/70503 ,  C07K14/70596 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2239/15 ,  A61K2239/17 ,  A61K2239/21 ,  A61K2239/29

Abstract: Disclosed herein is a chimeric antigen receptor (CAR) comprising a single-chain variable fragment specific to Globo H, a hinge and transmembrane domain, a co-stimulatory molecule, and a cytoplasmic domain. According to some embodiments of the present disclosure, the CAR further comprises a single-chain variable fragment specific to PD-L1, and optionally, a fragment crystallizable region of an immunoglobulin. Also disclosed herein are isolated nucleic acids encoding the CAR pharmaceutical kits comprising the isolated immune cells expressing the CAR, and methods of treating cancers by using isolated immune cells.